Bsx stock forecast 2025 in medtech sector peer comparisons

In medtech sector peer comparisons, BSX stock forecast 2025 ranks among the top quartile for ROE and ROI metrics. This competitive advantage stems from disciplined capital allocation and targeted M&A. This high-profile presentation highlighted the company’s ongoing commitment to innovation in endoscopy and underscored Boston Scientific’s leadership in advancing medical device technology. Many mega-cap stocks have started 2025 with a bang and we’ll be taking a closer look into each of them to learn why they’ve performed so well already. BSX stock forecast 2025 reflects strong backlog conversion rates and an expanding geographic footprint in Asia-Pacific. Currency-neutral sales growth targets remain robust, countering FX headwinds seen in